Presentation (CTI)

OBJECTIVES: In Germany, orphan drugs that exceed an annual revenue threshold of €30 million are subject to a full benefit reassessment and subsequent price negotiations, with implications for launch strategy and revenue. This study evaluated the impact of launch price, rebate levels, and timing of threshold attainment on revenue outcomes.
METHODS: A probabilistic simulation model was developed to estimate revenues under varying market access scenarios in Germany. Key parameters included: initial launch price, patient uptake rate (monthly increase), rebate after 6 months, and additional rebate after exceeding the €30 million threshold. Revenue outcomes were assessed over 12 to 48-month horizons. Probabilistic sensitivity analysis (PSA) was used to quantify uncertainty and identify the main drivers of revenue variability.
RESULTS: In the baseline scenario, assuming an annual treatment cost of €200,000 per patient and a mean uptake of 25 patients per month, mean revenue reached approximately €24 million after 12 months, with substantial uncertainty reflecting early market dynamics. Revenues increased over time, accompanied by greater variability driven primarily by uptake and pricing assumptions. Across all time horizons, launch price and patient uptake were the dominant determinants of revenue outcomes. The magnitude and timing of rebates exerted moderate but consistent influence, particularly over longer horizons. The timing of crossing the €30 million threshold emerged as a key inflection point: earlier attainment increased cumulative revenues but also accelerated exposure to additional rebates, thereby reducing marginal gains. Over four years, cumulative revenues varied widely (5th-95th percentile: approximately €95-€525 million), highlighting the strategic importance of balancing early pricing with long-term rebate exposure.
CONCLUSIONS: Revenue outcomes for orphan drugs in Germany are highly sensitive to launch price and patient uptake, while also being materially affected by rebate structures linked to the €30 million threshold. Optimizing launch price and uptake may be critical for maximizing long-term revenues under the German AMNOG framework.